Signalling Pathways Mediating the Effects of CD40-Activated CD40L Reverse Signalling on Inhibitory Medium Spiny Neuron Neurite Growth.

Open access · goldAbstract read

In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 55% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2.Brain and behavior · 2021
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paulina CarribaSchool of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, UK.ORCID 0000-0002-6980-2277

Alun M DaviesSchool of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, UK.

Cardiff University · GB

Funding

Wellcome Trust 103852

6 · The paper itself

Abstract

CD40-activated CD40L-mediated reverse signalling is a major physiological regulator of neurite growth from excitatory and inhibitory neurons in the developing central nervous system (CNS). Whereas in excitatory pyramidal neurons, CD40L reverse signalling promotes the growth and elaboration of dendrites and axons, in inhibitory GABAergic striatal medium spiny neurons (MSNs), it restricts neurite growth and branching. In pyramidal neurons, we previously reported that CD40L reverse signalling activates an interconnected and interdependent signalling network involving protein kinase C (PKC), extracellular regulated kinases 1 and 2 (ERK1/2), and c-Jun

Indexed as

Signal TransductionAnimalsCD40 AntigensCD40 LigandCell ProliferationCells, CulturedExtracellular Signal-Regulated MAP KinasesGABAergic NeuronsJNK Mitogen-Activated Protein KinasesMiceMice, Inbred C57BLModels, BiologicalNeuritesPhosphorylationProtein Interaction MapsProtein Kinase CCD40 AntigensCD40 LigandExtracellular Signal-Regulated MAP KinasesJNK Mitogen-Activated Protein KinasesProtein Kinase CSyk KinaseCD40L-reverse signallingERK1/2inhibitory neuronJNKneurite growthPKCSyk

Identifiers

PMID33917019

DOI10.3390/cells10040829

PMCPMC8067729

OpenAlexW3155493851

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.